Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13697067 | 0.87 | FDPS (0.38) | FDPSALDH1A1PKMLMNAMAPT | |
| SCHEMBL4174619 | 0.85 | FDPS (0.38) | FDPSALDH1A1PKMLMNAMAPT | |
| SCHEMBL14350297 | 0.81 | NPSR1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL13697079 | 0.80 | — | — | |
| SCHEMBL13697115 | 0.79 | SCN9A (0.31) | LY96SLC6A3 | |
| SCHEMBL13697097 | 0.76 | NLRP3 (0.34) | FDPS | |
| SCHEMBL14350282 | 0.73 | MIF (0.46) | ALDH1A1PKMMAPT | |
| SCHEMBL6374179 | 0.73 | TDP1 (0.37) | ALDH1A1MAPT | |
| SCHEMBL6374183 | 0.73 | TDP1 (0.37) | ALDH1A1MAPT | |
| SCHEMBL14443180 | 0.72 | CYP1A2 (0.38) | FDPSALDH1A1PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227600-A1 | 4-(PYRAZINE-2-YL) -PYRROLIDINE -2-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF AS HEPATITIS C VIRUS INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20070270475-A1 | 4-Methoxy-Pyrrolidine-2-Carboxylic Acid Compounds and Derivatives Thereof as Hepatitis C Virus Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270475-A1 | 4-Methoxy-Pyrrolidine-2-Carboxylic Acid Compounds and Derivatives Thereof as Hepatitis C Virus Inhibitors | HAVCR2, BCKDK, ZC3HAV1L | FDPS 2009/4885ALDH1A1 67/4885PKM 214/4885 |
| US-20090227600-A1 | 4-(PYRAZINE-2-YL) -PYRROLIDINE -2-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, ZC3HAV1L | FDPS 3314/4885ALDH1A1 164/4885PKM 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.